Photo: Dado Ruvic / REUTERS
According to a report in the New York Times this Tuesday, the US federal health authorities want to demand an immediate suspension of the use of the Covid-19 vaccine from Johnson & Johnson.
According to the report, six recipients of the dose in the US developed blood clots, the newspaper said, citing officials briefed on the decision.
All six recipients were women between the ages of 18 and 48 years.
One woman died and a second Nebraska woman was hospitalized in critical condition, the newspaper reports.
The responsible Food and Drug Administration, Johnson & Johnson and the Centers for Disease Control and Prevention have so far not responded to inquiries from the Reuters news agency.
The requested stop by US regulators comes less than a week after the European Medicines Agency announced that it would examine rare blood clots in four people in the US who had received vaccination with the Johnson & Johnson vaccine.
The vaccine has so far been administered more than 6.8 million times in the United States.
The Johnson & Johnson vaccine was approved in the EU in mid-March, but, unlike in the USA, is not yet in use there.
The EU Commission assumes that the active ingredient will be delivered from April 19.
A total of 55 million cans are to be delivered in the second quarter.
In contrast to the other vaccines, only one injection is required for comprehensive protection.
Last week, several countries, including Germany, advised against using the AstraZeneca vaccine in people under the age of 60.
The reason for this were isolated cases of blood clots in the cerebral veins.
On Wednesday, Ema had re-examined the cases at AstraZeneca found that there was a connection.
According to Ema, the frequency of reported incidents with blood clots in the brain is around one in 100,000.
The Ema continued to give the unreserved green light for use.
The drug authority explained that the benefits of the active ingredient should be rated higher than the risks.
As with AstraZeneca, the US company's vaccine is a vector vaccine that uses harmless viruses as delivery vehicles.
AstraZeneca uses a human-safe chimpanzee adenovirus (ChAdOx1) as a vector.
Johnson & Johnson
also uses an adenovirus, but a human one (Ad26)
jat / Reuters